Skip to main content
Show — Main navigation
Hide — Main navigation
Hair & Scalp
Expert Insights in Derm
Resident Journal Club Blog
Centers of Excellence
AAD Summer Meeting
SDPA Fall Conference
AAD VMX 2020
Music City SCALE
Centers of Excellence
Is Capecitabine Beneficial For Preventing Precancerous and Cancerous Skin Lesions?
A recent systematic review investigated the effectiveness of capecitabine for the prevention of precancerous and cancerous skin lesions, including squamous cell carcinoma.
News - July 2020
HS Diagnosis Can Take Up to 10 Years
Findings from a recent study showed patients with hidradenitis suppurativa experienced significant delays in receiving a diagnosis, and these delays were associated with more severe disease burden.
New Topical Acne Treatment Safe and Effective for Pediatric Patients
A recent pooled analysis of two phase 3 randomized clinical trials showed a new once-daily lotion formulation was safe, effective, and well-tolerated among pediatric patients with moderate to severe acne.
Are Chilblains Associated With COVID-19?
Findings from two European studies published in JAMA Dermatology assessed the potential association between chilblains and COVID-2019.
Is AD Associated With Cancer?
Findings from two large cohort studies highlighted the potential association between atopic dermatitis (AD), overall and specific cancer risks, and the influence of AD severity on this risk.
Bullous Pemphigoid Associated With Several Medications
Findings from a recent systematic review and meta-analysis showed an association between the development of bullous pemphigoid and the use of several medications.
Adalimumab Is Effective In Real-World Setting
A recent poster study, presented at AAD VMX 2020, showed that adalimumab effectively reduced hidradenitis suppurativa activity among patients at an outpatient dermatology center.
News - June 2020
Investigational Biologic Shows Promise for Psoriasis
A recent study demonstrated the safety and long-term effectiveness of bimekizumab, with participants maintaining high PASI scores through 60 weeks of treatment.
Stay in the know.
The Dermatologist Newsletter
Back to Top